New molecular entity: Trospium

Spero Therapeutics was seeking approval for tebipenem HBr oral tablets for treatment of adult patients with complicated urinary tract infection. The FDA has requested an additional clinical trial.

Approved in March, Tlando is an oral testosterone that doesn’t require dose titration.

Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.

Livmarli is the first drug approved for Alagille syndrome.

Regeneron also announced an expanded contract with the U.S. government for the purchase of additional doses of REGEN-COV.

Point32Health is the name of the not-for-profit health care organization formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan.